US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
October 23, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
October 21, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
October 20, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
October 20, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
October 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
October 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
October 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
October 16, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
October 15, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
October 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of Verona Pharma
October 07, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
VRNA
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
October 01, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
September 19, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
September 19, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
September 19, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
September 11, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
September 02, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
September 02, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
August 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
August 28, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
August 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
August 25, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
August 19, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
August 12, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
July 29, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2025 Dividend
July 22, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
July 14, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
July 10, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
July 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
VRNA
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
July 08, 2025
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
